ArticleOncoimmunology2016
Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.
Article in Oncoimmunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- A potential mechanism of tumor immune escape: Regulation and application of soluble natural killer group 2 member D ligands (Review).Oncology reports · 2024Review
- Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance.Frontiers in oncology · 2022Review
- Cancer immunotherapy: it's time to better predict patients' response.British journal of cancer · 2021Review
- Review
- Identification of prognostic genes and tumor-infiltrating immune cells in the tumor microenvironment of esophageal squamous cell carcinoma and esophageal adenocarcinoma.Translational cancer research · 2021Article
- Review
- Article
- SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.Journal for immunotherapy of cancer · 2020Article
- Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects.Cancers · 2020Review
- Prognostic value of novel immune-related genomic biomarkers identified in head and neck squamous cell carcinoma.Journal for immunotherapy of cancer · 2020Article
- Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells-An Update.Pharmaceutics · 2020Review
- Immune signature profiling identified prognostic factors for gastric cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2019Article
- Th17 Cells Paradoxical Roles in Melanoma and Potential Application in Immunotherapy.Frontiers in immunology · 2019Review
- Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers.Seminars in cancer biology · 2018Review
- Immune Profiling of Cancer Patients Treated with Immunotherapy: Advances and Challenges.Biomedicines · 2018Review
- Immunotherapy biomarkers 2016: overcoming the barriers.Journal for immunotherapy of cancer · 2017Article
- Immune signature profiling identified predictive and prognostic factors for esophageal squamous cell carcinoma.OncoimmunologyArticle
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical activity was observed in metastatic melanoma (MM) patients treated with ipilimumab (IPI) combined with fotemustine (FTM) in the phase II NIBIT-M1 study. Peripheral blood mononuclear cells (PBMCs) and serum were collected from MM patients at pre- and at weeks 12 and 24 post-treatment. A comprehensive phenotypic and functional immunomonitoring of circulating T cells, and the detection of soluble immunoregulatory molecules was carried out and correlated with clinical outcome. The frequency at baseline and along the treatment of circulating T central memory cells expressing activation/differentiation markers, such as CD3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.